S. Abdullaev

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Background In the phase 2 multicohort CheckMate 142 study (NCT02060188), nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety...

S. Abdullaev ;

A. Memaj ;

M. Lei ;

Scott Kopetz , MD, PhD;

M. Overman ;

A. Hill ;

K. Wong ;

T. Andre ;

Eric Van Cutsem , MD, PhD;

Sara Lonardi ;

H. Lenz ;

F. Gelsomino ;

M. Aglietta ;

M. Morse ;

Ryan M. McDermott ;

M. Sawyer ;

A. Hendlisz ;

B. Neyns ;

07/02/2021

A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Background Patients with MSI-H/dMMR mCRC treated with chemotherapy have poorer outcomes than patients with microsatellite stable/MMR proficient mCRC. Pembrolizumab monot...

T. Andre ;

Sara Lonardi ;

S. Abdullaev ;

M. Lei ;

L. Jensen ;

C. De la Fouchardiere ;

E. Elez ;

J. Bennouna ;

G. Mendez ;

J. Li ;

Eric Van Cutsem , MD, PhD;

E. Goekkurt ;